Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation

Table 2 Baseline patient demographics and clinical characteristics in the tacrolimus group n (%)

	Total (n = 529)	Low-dose TAC (n = 113)	Low-dose TAC with MMF (n = 235)	High-dose TAC (n = 61)	High-dose TAC with MMF (n = 120)	P value
Age (yr)	44.00 ± 9.25	45.00 ± 9.61	44.86 ± 9.21	42.93 ± 8.83	44.98 ± 9.20	NS
Gender	448/81	95/18	200/35	51/10	102/18	NS
Donor type	368/161	102/11	143/92	49/12	74/46	< 0.001
MELD score	13.54 ± 7.96	15.03 ± 8.34	13.15 ± 7.85	13.48 ± 6.59	12.94 ± 8.37	NS
Renal dysfunction pre-LT	46 (8.7)	15 (13.3)	16 (6.8)	8 (13.1)	7 (5.8)	NS
Post-LT AKI	80 (15.1)	22 (19.5)	33 (14.0)	11 (18.0)	14 (11.7)	NS
Post-LT AR	53 (10.0)	15 (13.3)	18 (7.7)	10 (16.4)	10 (8.3)	NS
Post-LT CR	13 (2.5)	3 (2.7)	5 (2.1)	2 (3.2)	3 (2.5)	NS
Primary diagnosis						NS
Tumors	265 (50.1)	61 (54.0)	107 (45.5)	35 (57.4)	62 (51.7)
Cirrhosis	182 (34.4)	39 (34.5)	89 (37.9)	17 (27.9)	37 (30.8)
Chronic active hepatitis	36 (6.8)	9 (8.0)	12 (5.1)	4 (6.6)	11 (9.2)
Others	46 (8.7)	4 (3.5)	27 (11.5)	5 (8.2)	10 (8.3)
Viral infection						NS
HBV infection	435 (82.2)	95 (84.1)	191 (81.3)	48 (78.7)	101 (84.2)
HCV infection	8 (1.5)	2 (1.8)	6 (2.6)	0	0

Age: Age at transplantation; LT: Liver transplantation; DDLT: Deceased donor liver transplantation; LDLT: Living donor liver transplantation; MELD: Mayo end-stage liver disease; AKI: Acute kidney injury; AR: Acute rejection; CR: Chronic rejection; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NS: Not significance; TAC: Tacrolimus; CSA: Cyclosporine A.